Sugi Predict

Sugi Predict / Compounds / SCHEMBL320439

SCHEMBL320439

SCHEMBL320439

COC[C@@H](C)OS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.43
▸ LMNA P02545 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ GAA P10253 2/20 0.41
▸ GBA1 P04062 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CA2 P00918 4/20 0.38
▸ CA9 Q16790 3/20 0.38
▸ CA1 P00915 3/20 0.38
▸ CA12 O43570 2/20 0.38
▸ CA7 P43166 2/20 0.38
▸ CA3 P07451 1/20 0.38
▸ CA6 P23280 1/20 0.38
▸ CA5A P35218 1/20 0.38
▸ CA5B Q9Y2D0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL320440 1.00 ALDH1A1 (0.43) ALDH1A1LMNAHPGDHTTGAA
SCHEMBL30001425 1.00 ALDH1A1 (0.43) ALDH1A1LMNAHPGDHTTGAA
SCHEMBL6118689 1.00 ALDH1A1 (0.43) ALDH1A1LMNAHPGDHTTGAA
SCHEMBL21798639 0.98 ALDH1A1 (0.42) ALDH1A1LMNAHPGDHTTGAA
SCHEMBL28492758 0.89 ALDH1A1 (0.41) ALDH1A1LMNAHPGDHTTGAA
SCHEMBL6118366 0.89 GAA (0.37) ALDH1A1LMNAHPGDHTTGAA
SCHEMBL1148936 0.86 GAA (0.41) ALDH1A1LMNAGAAGBA1CYP3A4
SCHEMBL2337309 0.86 GAA (0.41) ALDH1A1LMNAGAAGBA1CYP3A4
SCHEMBL6118591 0.85 ALDH1A1 (0.42) ALDH1A1LMNAHPGDHTTGAA
SCHEMBL14258473 0.85 MAPT (0.39) ALDH1A1LMNAHPGDGAACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118745165-A C-N coupling method and method for preparing dimethenamid S configuration by using C-N coupling 山东京博农化科技股份有限公司 2024-10-08 — — CN disclosed
EP-3613737-B1 NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2021-12-29 — — EP disclosed
US-10952999-B2 Inhibitor of cyclin-dependent kinase CDK9 GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2021-03-23 — — US disclosed
CN-108727363-B Novel cyclin dependent kinase CDK9 inhibitor 劲方医药科技(上海)有限公司 2020-06-19 — — CN disclosed
EP-3433254-B1 NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS GLAXOSMITHKLINE IP DEV LTD (GB) 2020-06-17 — — EP disclosed
EP-3433254-B1 NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS GLAXOSMITHKLINE IP DEV LTD (GB) 2020-06-17 — — EP disclosed
US-20200078343-A1 NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 Shanghai Jiongshuo Pharmaceutical Technology Co., Ltd. (CN) 2020-03-12 — — US disclosed
EP-3613737-A1 NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 Genfleet Therapeutics (Shanghai) Inc. (CN) 2020-02-26 — — EP disclosed
US-20190112306-A1 NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-04-18 — — US disclosed
US-20190112306-A1 NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-04-18 — — US disclosed
US-8076481-B2 Chemical process 632 ASTRAZENECA AB (SE) 2011-12-13 — — US disclosed
US-8076481-B2 Chemical process 632 ASTRAZENECA AB (SE) 2011-12-13 — — US disclosed
US-20100210621-A1 CRYSTALLINE POLYMORPHIC FORM 631 ASTRAZENECA AB (SE) 2010-08-19 — — US disclosed
US-20100210621-A1 CRYSTALLINE POLYMORPHIC FORM 631 ASTRAZENECA AB (SE) 2010-08-19 — — US disclosed
US-20100210621-A1 CRYSTALLINE POLYMORPHIC FORM 631 ASTRAZENECA AB (SE) 2010-08-19 — — US disclosed
US-20100210841-A1 CHEMICAL PROCESS 632 ASTRAZENECA AB (SE) 2010-08-19 — — US disclosed
US-20100210841-A1 CHEMICAL PROCESS 632 ASTRAZENECA AB (SE) 2010-08-19 — — US disclosed
US-20100210841-A1 CHEMICAL PROCESS 632 ASTRAZENECA AB (SE) 2010-08-19 — — US disclosed
WO-2010092386-A1 CRYSTALLINE POLYMORPHIC FORM 631 ASTRAZENECA AB (SE) 2010-08-19 — — WO disclosed
WO-2010092387-A1 PROCESS FOR PREPARATION OF BEZOYL AMINO HETEROCYCLYL COMPOUNDS ASTRAZENECA AB (SE) 2010-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210841-A1 CHEMICAL PROCESS 632 F12, XDH, REN ALDH1A1 1971/4885LMNA 1850/4885HPGD 3158/4885
US-10952999-B2 Inhibitor of cyclin-dependent kinase CDK9 CDK9, CDK19, CDK1 ALDH1A1 2758/4885LMNA 1204/4885HPGD 1376/4885
US-20190112306-A1 NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS ITGB6, ITGA6, GP6 ALDH1A1 1251/4885LMNA 1425/4885HPGD 2052/4885
US-20100210621-A1 CRYSTALLINE POLYMORPHIC FORM 631 GCKR, GCK, HK1 ALDH1A1 1205/4885LMNA 3278/4885HPGD 3269/4885
US-20200078343-A1 NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 CDK9, CDK19, CDKL1 ALDH1A1 2840/4885LMNA 1578/4885HPGD 1548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.